Date: 2015-09-03
Type of information: R&D agreement
Compound: pan-RAF inhibitor program
Company: Horizon Discovery (UK) Redx Pharma (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: kinase inhibitor
Disease:
Details: * On September 3, 2015, Horizon Discovery, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, and Redx Pharma announced a research collaboration to progress Redx’s novel pan-RAF inhibitor program, for out-licensing in oncology indications including colorectal cancer. Redx’s pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-RAF inhibitors have been designed to overcome resistance mechanisms seen with first generation RAF inhibitors in colorectal cancer. As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx’s pan-RAF inhibitors and support Redx as it seeks to rapidly move this rare class of compounds towards partnering.
Financial terms: Under the terms of the agreement, Horizon and Redx will bear costs proportionate to respective research activities. The successful partnering of a program asset with a pharmaceutical company is expected to deliver a material return on Horizon’s investment from any upfront payment, a share of future milestones and a share of future product royalties.
Latest news:
